IRWD 株価分析 — IRONWOOD PHARMACEUTICALS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
IRWD に関するよくある質問
IRWDのPER(株価収益率)は?
IRONWOOD PHARMACEUTICALS INC(IRWD)は現在PER 6.01倍で取引されています。
IRWDのROE(自己資本利益率)は?
IRONWOOD PHARMACEUTICALS INCのROEは-47.05%です。
IRWDの配当利回りは?
IRONWOOD PHARMACEUTICALS INCの配当利回りは0.00%です。
IRWDの品質スコア(Quality Score)は?
当社のAIはIRWDの総合財務品質を100点中69点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
IRWDは今が買い時ですか?
当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
IRWDはどのセクターに属しますか?
IRONWOOD PHARMACEUTICALS INCはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます(NASDAQ市場)
IRWD AI Analysis Summary
Our AI summary for IRWD: IRONWOOD PHARMACEUTICALS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 6.01, ROE of -47.05%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.23
Price
0.50
(13.40%)
Day Change
|
|
|---|
IRWD, ファンダメンタルスコアはok ( ファンダメンタル = 69) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is good , ...
| Deepscope 分析 |
|
63% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
430
|
| Magic Formula Rank by ROE |
430
|
| Magic Formula Rank by ROIC |
109
|
| Price | 4.23 |
| PBV / Sector |
-2.83 / 3.22
|
| Earning Per Share | 0.70 |
| PE / Sector |
6.01 / 29.79
GREAT
|
| PEG or PE/Growth / Sector |
0.01 / 0.13
GREAT
|
| Average 1M Daily Value |
9.01 M
|
| Average 1W Daily Value |
7.79 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
72% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:02 |
| Symbol | IRWD |
| Name | IRONWOOD PHARMACEUTICALS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 164.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 614.01 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 Summer Street, Boston, MA, United States, 02110
Phone: 617 621 7722
Website: https://ironwoodpharma.com
Employees: 100
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google